High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

Abstract Purpose We sought to understand the clinical course and molecular phenotype of patients who showed disease progression after programmed cell death ligand 1 (PD-L1) inhibitor treatment but subsequently responded to PD-1 inhibitor treatment. We also explored the response to PD-1-axis targeted...

Full description

Bibliographic Details
Main Authors: Xi Chen, Haiying Kong, Linxiang Luo, Shuiyun Han, Tao Lei, Haifeng Yu, Na Guo, Cong Li, Shuailing Peng, Xiaowu Dong, Haiyan Yang, Meijuan Wu
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Cancer
Subjects:
Hodgkin lymphoma
PD-1 inhibitor
PD-L1 inhibitor
PD-L2
Molecular phenotype
Tumor microenvironment
Online Access:https://doi.org/10.1186/s12885-021-09028-4

Internet

https://doi.org/10.1186/s12885-021-09028-4

Similar Items